Engineered Immune Cells in Cancer Immunotherapy (EICCI)

  • 166k

    Total Downloads

  • 605k

    Total Views and Downloads

Download PDFDownload EPUB

Submit your idea

Select the journal/section where you want your idea to be submitted:

Submit your manuscript summarySubmit your manuscript

About this Research Topic

Submission closed

Background

Over the past decades, great advances in the knowledge of adoptive cell therapy (ACT) and in engineering of T cells with tumor antigen-targeting receptors have accelerated the clinical development of this strategy at an unparalleled pace. T cells have been engineered with either a T cell receptor (TCR) or a chimeric antigen receptor (CAR) that combines the antibody-derived part with activating and co-stimulatory signaling of T cells. The targeting of endogenous tumor antigens with T cells engineered with a TCR has shown an initial clinical success. However, clinical studies are ongoing to evaluate the efficacy of targeting neoantigens generated by tumor-specific non-synonymous mutations. Strikingly, promising results were recently described when CAR-T cells were used to target CD19 expressing refractory B-cell malignancies, with complete response rates of 50-90% and durable improvement of overall survival. These unprecedented advances in the clinical efficacy of CAR-T cells led to the approval of two products by the FDA and more recently by the EMA, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). In addition, promising results have been recently observed also for the treatment of other types of hematological malignancies, such as multiple myeloma.

These biological “living drugs” are produced by isolating patient’s T lymphocytes from peripheral blood mononuclear cells (PBMCs) and engineering these T cells with either gamma-retroviral (RV) or lentiviral (LV) vectors that encode for either TCRs or CARs. However, their clinical grade manufacturing is complex, requiring good manufacturing practice (GMP) facilities, a long timeline for engineering the cellular product and the availability of patient PBMCs of good quality. Serious side effects and adverse events, including cytokine release syndrome (CRS) and neurologic problems, represent additional major issues that have been documented in CAR-T cell treated patients. The experience thus far gained in this field by the principle clinical centers developing these types of clinical studies has led to strategies to control and, in most cases, even resolve these adverse events. However, further studies on the mechanisms involved in these adverse reactions and how to avoid them will grant important advances in the efficacy and safety of engineered T cells. Moreover, dose, phenotype, tumor burden, the design of receptors and their expression and the choice of target antigens are critical points that require ad hoc investigations.

In order to provide patients with immediate treatment, several groups have designed various strategies to obtain donor-derived allogeneic “off-the-shelf” CAR-T cells, with a few clinical studies already ongoing for patients with hematological malignancies. Gene editing platforms (e.g., CRISPR/CAS-9 or TALEN) to knock-out specific gene(s), such as TCR and HLA, are under development to overcome CAR-T cell-mediated graft-versus-host disease (GvHD) or host versus graft reactions, respectively. However, this approach still needs to be optimized in terms of manufacturing, reduction of the risk of toxicities and selection of the target genes.
This Research Topic will collect selected contributions in the following topics:

• The clinical evolution of CAR-T cell therapy.
• Targeting tumors with TCR engineered T lymphocytes.
• Optimizing the choice of target molecules and in vivo models for engineered T lymphocytes.
• Manufacturing implementation of engineered T cells and Pharma/Biotech perspectives.
• Allogeneic/”Off the Shelf” Therapy with CAR-T cells.
• Innovative approaches to improve the targeting of cancer cells.
• Regulatory and quality aspects of building clinical centers for advanced therapy medicinal products.

Contributors are welcome to submit Original Research, Method, Mini-review and Review articles related to the topics mentioned above and covered in the 1st International Workshop on Engineered Immune Cells in Cancer Immunotherapy (EICCI), held at Sidra Medicine in Doha, Qatar, on 15th-16th February 2019EICCI Workshop.

Topic Editor Dr. Francisco Martin Molina is the founder of LentiStem Biotech, a Start-up focused on the development of SAFER AND MORE EFFICIENT gene delivery systems for gene-cell therapy applications with special focus on lentiviral vectors and its applications to the genetic correction of rare disorders and cancer immunotherapy. Topic Editor Prof. Cameron Turtle receives financial support from Juno Therapeutics and Nektar Therapeutics. All other Topic Editors declare no competing interests with regards to the Research Topic subject.

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic editors

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

    In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

     

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

     

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.

     

Participating Journals

Impact

  • 605kTopic views
  • 432kArticle views
  • 166kArticle downloads
View impact